Phathom Pharmaceuticals, Inc. (PHAT): Capital Expenditures
$229.0K
Year ended 2025-12-31
$219.0K
Trailing 12 months to 2026-06-30
-39.6%
3-year compound annual growth
-26.1%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $229.0K | +69.6% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $135.0K | -91.7% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $1.63M | +57.0% | 2025-03-06, From 2023-01-01 |
| 2022-12-31 | $1.04M | +217.4% | 2024-06-14, From 2022-01-01 |
| 2021-12-31 | $328.0K | -68.5% | 2023-02-28, From 2021-01-01 |
| 2020-12-31 | $1.04M | +687.9% | 2022-03-01, From 2020-01-01 |
| 2019-12-31 | $132.0K | n/a | 2021-03-30, From 2019-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | $229.0K | +69.6% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $16.44M | -4.7% |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | $187.0K | n/a |
| Lifevantage Corp (LFVN) | 2026-06-30 | $3.57M | +160.5% |
| Stoke Therapeutics, Inc. (STOK) | 2025-12-31 | $670.0K | +230.0% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $13.15M | -55.7% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $953.0K | n/a |
| Liquidia Corp (LQDA) | 2025-12-31 | $4.34M | -12.4% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $317.0K | -81.4% |
Compare PHAT, CYRX, SNDX, LFVN side by side · Screen every company in Pharmaceutical Preparations ↗